Equities

Imunon Inc

Imunon Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.03
  • Today's Change-0.04 / -3.74%
  • Shares traded508.17k
  • 1 Year change-5.50%
  • Beta2.1301
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments163449
Total Receivables, Net00.130.11
Total Inventory------
Prepaid expenses2.552.782.45
Other current assets, total------
Total current assets183752
Property, plant & equipment, net2.350.701.17
Goodwill, net----0
Intangibles, net--013
Long term investments04.506.00
Note receivable - long term------
Other long term assets0.050.050.18
Total assets224474
LIABILITIES
Accounts payable3.523.592.55
Accrued expenses3.885.033.72
Notes payable/short-term debt000
Current portion long-term debt/capital leases01.420
Other current liabilities, total--00.50
Total current liabilities7.39106.77
Total long term debt04.615.85
Total debt06.045.85
Deferred income tax------
Minority interest------
Other liabilities, total1.1405.63
Total liabilities8.531518
SHAREHOLDERS EQUITY
Common stock0.090.070.06
Additional paid-in capital402398389
Retained earnings (accumulated deficit)(388)(369)(333)
Treasury stock - common(0.09)(0.09)(0.09)
Unrealized gain (loss)------
Other equity, total0.060.03(0.01)
Total equity132956
Total liabilities & shareholders' equity224474
Total common shares outstanding9.407.445.77
Treasury shares - common primary issue0.000.000.00
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.